Intrexon (NYSE: XON) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Intrexon to related businesses based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations for Intrexon and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intrexon 0 1 5 0 2.83
Intrexon Competitors 534 2414 6615 125 2.65

Intrexon currently has a consensus target price of $38.50, suggesting a potential upside of 189.91%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.37%. Given Intrexon’s stronger consensus rating and higher probable upside, research analysts plainly believe Intrexon is more favorable than its rivals.

Valuation & Earnings

This table compares Intrexon and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intrexon $190.93 million -$186.61 million -11.86
Intrexon Competitors $217.29 million -$39.39 million -68.25

Intrexon’s rivals have higher revenue and earnings than Intrexon. Intrexon is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Intrexon and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intrexon -66.88% -18.68% -11.34%
Intrexon Competitors -3,317.85% -535.30% -40.95%

Risk and Volatility

Intrexon has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Intrexon’s rivals have a beta of 1.54, suggesting that their average stock price is 54% more volatile than the S&P 500.

Insider and Institutional Ownership

77.5% of Intrexon shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 55.1% of Intrexon shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Intrexon beats its rivals on 8 of the 12 factors compared.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive News & Stock Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related stocks with our FREE daily email newsletter.